Amphastar Pharmaceuticals, Inc. (AMPH) Reached 12-Month High on Feb, 13

During 2018 Q3 the big money sentiment decreased to 1. That’s change of 0.11, from 2018Q2’s 1.11. 14 investors sold all, 29 reduced holdings as Amphastar Pharmaceuticals, Inc. ratio is negative. 32 grew positions while 11 funds acquired positions. Funds hold 20.26 million shares thus 2.33% more from 2018Q2’s 19.80 million shares.
Sei Communication owns 67,934 shs. Aperio Grp Ltd Liability reported 20,671 shs stake. State Bank Of Montreal Can reported 2,184 shs. Mackay Shields Limited Liability Company owns 205,100 shs. Louisiana State Employees Retirement System owns 15,300 shs for 0.01% of their capital. Kbc Grp Inc Nv holds 0.01% or 71,653 shs. Paloma Mngmt Communication has invested 0% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Citigroup has 37,127 shs. Renaissance Tech Ltd Limited Liability Company has invested 0% of its capital in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Geode Capital Management Limited Liability Corp reported 0% of its capital in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Teachers Retirement Systems Of The State Of Kentucky accumulated 7,031 shs or 0% of the stock. Blackrock owns 5.99M shs. State Street reported 1.05 million shs or 0% of all its holdings. 44,216 were accumulated by Boston Advisors Lc. Alliancebernstein Ltd Partnership has 0% invested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) for 124,100 shs.

By touching $23.81 share price a new 1-year high was achieved by Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). On Feb, 13 it was published by Barchart.com. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has $1.10 billion market cap. $43.92 million more could be NASDAQ:AMPH valuation at $24.76 share price.

Ticker’s shares touched $23.81 during the last trading session after 0.21% change.Amphastar Pharmaceuticals, Inc. has volume of 43,173 shares. Since February 13, 2018 AMPH has risen 20.09% and is uptrending. The stock outperformed the S&P 500 by 20.09%.

Investors wait Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)’s quarterly earnings on March, 11., according to Zacks. Analysts forecast $0.11 earnings per share. That’s $0.01 up or 10.00 % from 2018’s earnings of $0.1. If earnings per share of $0.11 is published the profit of AMPH could hit $5.07M giving it 54.11 P/E. After $0.12 earnings per share was published previous quarter, analysts now see negative EPS growth of -8.33 % for Amphastar Pharmaceuticals, Inc..

For more Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) news brought out recently go to: Nasdaq.com, Seekingalpha.com, Globenewswire.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Amphastar Pharmaceuticals (AMPH) Matches Q3 Earnings Estimates – Nasdaq” brought out on November 08, 2018, “Adamis: An Exciting Pipeline Candidate Moves Forward – Seeking Alpha” on December 19, 2018, “Amphastar Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018 – GlobeNewswire” with a publish date: May 10, 2018, “MannKind Negotiates Debt With Deerfield – Issues Shares In Process – Seeking Alpha” and the last “Does Amphastar’s Pipeline Warrant Its Valuation? – Seeking Alpha” with publication date: December 13, 2017.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products.The firm is valued at $1.10 billion. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.Currently it has negative earnings. The company's product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.